An interventional study of 0.12% Chlorhexidine Gluconate Mouthwash and 5% Morus Nigra Mouthwash in Periodontitis and Periodontal Disease, sponsored by Inonu University. Completed at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by Inonu University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Periodontitis by Inonu University — none open to participants now, none under way, none of them phase 3. Periodontitis · Inonu University.
Among the 11 studies in Periodontitis by Inonu University, this one is one of 3 that started in 2025, is one of 2 with no phase, and was the 3rd registered.
1,242 studies on the registry are indexed under Periodontitis; 304 are open to participants now.
Browse Periodontitis studies →None of the 11 studies in Periodontitis by Inonu University is open now. The open studies under Periodontitis, anywhere →
Of the 163 Periodontitis studies recruiting now, 80 (49%) set no upper age limit and 62 (38%) stop at 75 or younger; 12 take children under 18; 80 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2024; this study’s year is marked. 3 started in 2025.
This study's enrollment of 48 is close to the median of 44 across 850 interventional studies indexed under Periodontitis.
Median enrollment 50 across the 2 interventional studies, 72 across the 9 observational. Of the 11 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Inonu University is the lead sponsor of 399 studies on the registry; 98 are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 11 studies in Periodontitis by Inonu University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to evaluate and compare the clinical, biochemical, and microbiological effects of chlorhexidine and Morus nigra mouthwashes used as an adjunct to non-surgical periodontal treatment (scaling and root planing - SRP) in patients with periodontal diseases. The participants will be divided into three groups: a control group receiving only SRP, a group receiving SRP combined with chlorhexidine mouthwash, and a group receiving SRP combined with Morus nigra mouthwash. Clinical periodontal parameters, gingival crevicular fluid levels of inflammatory markers (including TNF-a, IL-1b, and IL-10), and subgingival plaque microbiological profiles (such as red complex bacteria and Fusobacterium) will be evaluated at baseline, 1 month, and 3 months after the treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Non-surgical periodontal treatment consisting of full-mouth scaling and root planing (SRP) using ultrasonic and hand instruments.
Procedure: Scaling and Root Planing (SRP)
As an adjunct to scaling and root planing, patients will rinse with 15 ml of 0.12% chlorhexidine gluconate mouthwash twice a day (morning and evening) for 1 minute. The duration of the intervention is 14 days.
Drug: 0.12% Chlorhexidine Gluconate Mouthwash · Procedure: Scaling and Root Planing (SRP)
As an adjunct to scaling and root planing, patients will rinse with 15 ml of a standardized mouthwash containing 5% Morus nigra extract twice a day (morning and evening) for 1 minute. The duration of the intervention is 14 days.
Drug: 5% Morus Nigra Mouthwash · Procedure: Scaling and Root Planing (SRP)
As an adjunct to SRP, patients were instructed to rinse with 15 ml of 0.12% chlorhexidine gluconate mouthwash twice daily (morning and evening) for 1 minute. The treatment duration was 14 days.
As an adjunct to SRP, patients were instructed to rinse with 15 ml of a standardized mouthwash containing 5% Morus nigra extract twice daily (morning and evening) for 1 minute. The treatment duration was 14 days.
All patients in the study underwent non-surgical periodontal therapy consisting of full-mouth scaling and root planing (SRP) using both ultrasonic devices and hand instruments.
Gingival Index (GI)
Evaluation of gingival inflammation using a scale of 0 to 3.
Time frame: Baseline (Day 0), 1 month, and 3 months after periodontal treatment.
Plaque Index (PI)
Evaluation of plaque accumulation using a scale of 0 to 3.
Time frame: Baseline (Day 0), 1 month, and 3 months after periodontal treatment.
Probing Depth (PD)
Measurement of the distance from the gingival margin to the bottom of the periodontal pocket.
Time frame: Baseline (Day 0), 1 month, and 3 months after periodontal treatment.
Clinical Attachment Level (CAL)
Measurement of the distance from the cementoenamel junction to the bottom of the periodontal pocket.
Time frame: Baseline (Day 0), 1 month, and 3 months after periodontal treatment.
Bleeding on Probing (BOP)
Evaluation of the presence or absence of bleeding within 30 seconds after probing. The result is recorded as a percentage of sites that bleed.
Time frame: Baseline (Day 0), 1 month, and 3 months after periodontal treatment.
Change in Gingival Crevicular Fluid (GCF) Inflammatory Markers
Analysis of TNF-a, IL-1b, and IL-10 levels in the gingival crevicular fluid using ELISA (or specific biochemical assay) to evaluate the local inflammatory response
Time frame: At baseline, 1 month, and 3 months after treatment
Change in Subgingival Plaque Microbiological Profile
Evaluation of subgingival plaque samples to determine the levels of red complex bacteria and Fusobacterium nucleatum using PCR (Polymerase Chain Reaction) analysis
Time frame: At baseline, 1 month, and 3 months after treatment
Plan to share: Yes — De-identified individual participant data that underlie the results reported in the published article will be shared
Supporting information: Study protocol, Statistical analysis plan
Time frame: Data will be available beginning 6 months and ending 36 months following article publication.
Access criteria: Data will be shared with researchers who provide a methodologically sound proposal. Requests for data sharing should be directed to the principal investigator via email
No publications or documents are linked to this record.
Ran from Mar 2025 to primary completion in Jan 2026, 9 months.
Of 484 non-industry interventional studies with no phase under Periodontitis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 31. This study's 9 months is below that.
Counting every sponsor, half of 498 studies reached it within 15 months; a quarter within 8 and three quarters within 31.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: start May 2025 → Mar 2025, primary completion Jun 2026 → Jan 2026 and completion Jul 2026 → Jan 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Chlorhexidine gluconate